Oxbryta Product Registry (Sickle Cell Disease)

Purpose of this Study

We are doing this study to learn more about the effects of the prescription drug Oxbryta (voxelotor) on sickle cell disease (SCD) when it is prescribed to patients. We want to keep track of the health of people with SCD who take this drug as part of their normal care.

Who Can Participate?

Eligibility

Adults and children who:
  • Are diagnosed with SCD
  • Started taking Oxbryta within the past 6 months or plan to begin taking Oxbryta in the future
For more information about this study, please contact the study team at stephanie.padrick@duke.edu.

Age Range

12-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will:
  • Fill out surveys about every 6 months during your regularly scheduled hematology visits
  • Give us permission to collect information from your medical records for research
Participation in this study will last up to 5 years. We will collect information related to your health for one year or less before you begin taking Oxbryta if you do not use it when you join the study, and we will collect information related to your health for up to 5 years while you are taking Oxbryta.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)

Principal Investigator

Nirmish
Shah

Protocol Number

PRO00108604

Phase

N/A

Enrollment Status

Open to Enrollment